Immunic Inc. (IMUX) PT Raised to $61 at BMO Capital, Following Drug Trial Results
BMO Capital analyst George Farmer raised the price target on Immunic Inc. (NASDAQ: IMUX) to $61.00 (from $40.00) while maintaining a Market Perform rating.
BMO Capital analyst George Farmer raised the price target on Immunic Inc. (NASDAQ: IMUX) to $61.00 (from $40.00) while maintaining a Market Perform rating.